Abstract
This article reviews the 2020 European Society for Photodynamic Therapy (Euro-PDT) Annual Congress. Cutting edge studies included assessment of immunohistochemical variables influencing response of basal cell carcinomas and Bowen’s disease to PDT with p53, the only biomarker associated with good response in both conditions. A further study indicated that analysis of molecular markers, such as PIK3R1, could help select patients with actinic keratoses who demonstrate the best response to daylight PDT. Novel delivery protocols include artificial daylight, and laser-assisted and textile PDT. The meeting learnt of novel indications including antimicrobial PDT, as well as methods to optimise daylight PDT, including combination therapy for actinic keratoses. Adverse events were reviewed and options for painless and efficient PDT assessed, including the effect of reduced drug-light interval. A smartphone application was also evaluated which may be used to assist clinicians and patients in effective dosing and timing of daylight PDT via computational algorithms using data from earth observation satellites, to send light and ultraviolet dose information directly to patients’ smart phones.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Morton CA, Szeimies R-M, Basset-Seguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications — actinic keratoses. Bowen’s disease and basal cell carcinomas. 1. J Eur Acad Dermatol Venereol 2019; 33: 2225–38.
Morton CA, Szeimies R-M, Basset-Seguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications — field cancerization, photo-rejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol 2020; 34: 17–29.
Wong TH, Morton CA, Collier N. British Association of Dermatologists and British Photodermatology Group guidelines for topical PDT 2018. Br J Dermatol 2019; 180: 730–9.
Photodynamic Therapy Service Guidance and Standards. Dec. 2018. Accessed 21/4/20. Available at: https://www.bad.org.uk/healthcare-professionals/clinical-services/service-guidance/pdt.
Gracia-Cazana T, Mascaraque M, Lucena SR, et al. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy. PLoS One 2019; 14: e0215537.
Gracia-Cazaña T, Salazar N, Vera-Álvarez J, et al. Clinical, histological and immunohistochemical markers of resistance to methyl aminolaevulinate photodynamic therapy in Bowen disease. Br J Dermatol 2018; 178: e13840.
Szeimies RM. Pain perception during photodynamic therapy: why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities. G Ital Dermatol Venereol 2018; 153: 793–9.
Ibbotson S, Wong T, Morton C, et al. Management of adverse effects of topical PDT. Br J Dermatol 2019; 180: 715–29.
O’Mahoney P, Khazova M, Eadie E, Ibbotson S. Measuring daylight: a review of dosimetry in daylight photodynamic therapy. Pharmaceuticals (Basel) 2019; 12: 4.
Fargnoli M, Piccioni A, Neri L, et al. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison study in Italy. J Eur Acad Dermatol Venereol 2015; 29: 1926–32.
Assikar S, Labrunie A, Kerob D, Couraud A, Bédane C. Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra-individual study. J Eur Acad Dermatol Venereol 2020; 34: 1730–5.
Heppt M, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 863–73.
Vicentini C, Vignion-Dewalle A, Thecua E, et al. Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase II clinical study evaluating the noninferiority of a new protocol involving irradiation with a light-emitting, fabric-based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the Aktilite CL 128 lamp. Br J Dermatol 2019; 180: 765–73.
Mordon S, Vignion-Dewalle A, Abi-Rached H, et al. The conventional protocol vs. a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, noninferiority clinical study. Br J Dermatol 2020; 182: 76–84.
Maire C, Vignion-Dewalle A, Cartier H, Mordon S. Artificial white light photodynamic therapy for actinic keratosis: a study of 38 patients in private office practice. J Eur Acad Dermatol Venereol 2020; 34: e165–7.
Togsverd-Bo K, Halldin C, Sandberg C, et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial. Br J Dermatol 2018; 178: 903–9.
Togsverd-Bo K, Lei U, Erlendsson AM, et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients — a randomized controlled trial. Br J Dermatol 2015; 172: 467–74.
Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2010; 36: 652–8.
Todd B, Lesar A, O’Mahoney P, Eadie E, Ibbotson S. Is there an optimal irradiation dose for photodynamic therapy: 37 J cm2 or 75 J cm−2? Br J Dermatol 2020; 182: 1287–8.
Acknowledgements and disclosures. Acknowledgements: the speakers mentioned in this article presented their data at the Euro-PDT Annual Congress 2020 and provided consent to inclusion of overviews of their presentations in this publication. The full text of each communication or poster can be found in the congress abstract book, available online at: http://euro-pdt.org/. Dr Morton, Prof Szeimies and Prof Braathen prepared this written article based on the presentations. Support: the authors receivedno support in the writing of this manuscript. Conflicts of interest: Dr Morton, Prof Szeimies and Prof Braathen received speaker fees and travel support from Galderma.
Author information
Authors and Affiliations
Corresponding author
Additional information
This congress took place on 28th–29th February 2020 in Seville, Spain.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Morton, C.A., Szeimies, RM. & Braathen, L.R. Review of the European Society for Photodynamic Therapy (Euro-PDT) Annual Congress 2020. Eur J Dermatol 31, 17–21 (2021). https://doi.org/10.1684/ejd.2021.3973
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2021.3973